# Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C

Source: https://onco.cc/trials/nct06897644/  
OnCo record `nct06897644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cAPOX (capecitabine, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.

## Summary

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. is a phase 3, randomised interventional study registered as NCT06897644 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 340 participants, started 2025-03-27 and due to reach its primary completion in 2029-01-01. Interventions recorded: Oxaliplatin; Irinotecan (CPT-11); Leucovorin; 5-FU (5-fluorouracil); gemcitabine; Nab-paclitaxel. Conditions listed: Pancreatic Adenocarcinoma Advanced or Metastatic. Primary outcome: Overall Survival (OS). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic adenocarcinoma eligible for treatment in the first-line setting". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANThEON
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06897644
- Phase: 3
- Setting: Gemcitabine Plus Nab-PAclitaxel as Switch maiNTEnance Versus cONtinuation of Modified FOLFIRINOX as First-line Chemotherapy in Patients With Advanced Pancreatic Cancer: the PANThEON Phase III Trial
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT06897644: https://clinicaltrials.gov/study/NCT06897644

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06897644.json